Table A1.
Baseline and week 4 characteristics of study participants.
| Clinical Characteristics | Metronidazole-Inulin (n = 20) |
Placebo-Inulin (n = 20) |
Placebo-Placebo (n = 20) |
Total (n = 60) |
|---|---|---|---|---|
| Age (y) | 50.6 (10.4) | 51.5 (13.5) | 46.7 (11.2) | 49.6 (11.8) |
| Sex (M:F) | 10:10 | 8:12 | 13:7 | 31:29 |
| Body mass index (kg/m2) | ||||
| Baseline Week 4 |
31.4 (3.4) 29.0 (3.4) |
30.9 (3.5) 27.1 (7.3) |
32.6 (4.3) 29.9 (3.8) |
31.6 (3.8) 29.1 (3.6) *** |
| Weight (kg) | ||||
| Baseline Week 4 |
89.8 (12.4) 83.0 (12.0) |
85.6 (15.5) 73.7 (21.6) |
94.2 (15.9) 86.4 (13.4) |
89.9 (14.9) 82.7 (13.3) *** |
| Waist:hip ratio | ||||
| Baseline Week 4 |
0.98 (0.07) 0.93 (0.06) |
0.99 (0.04) 0.94 (0.05) |
0.98 (0.06) 0.92 (0.08) |
0.98 (0.05) 0.96 (0.06) *** |
| Blood pressure (mm Hg) | ||||
| Systolic at Baseline Systolic at Week 4 Diastolic at Baseline Diastolic at Week 4 |
132 (16) 121 (13) 83 (10) 76 (10) |
129 (14) 121 (16) 77 (10) 74 (10) |
125 (17) 121 (21) 77 (11) 74 (14) |
129 (16) 121 (17) *** 79 (11) 75 (11) *** |
| ALT (U/L) | ||||
| Baseline Week 4 |
64.0 (28.6) 59.8 (25.0) |
70.0 (26.1) 53.3 (22.0) |
60.2 (28.1) 46.2 (21.1) |
64.7 (27.4) 53.2 (23.1) ** |
| AST (U/L) | ||||
| Baseline Week 4 |
34 (25, 46) 41 (31, 55) |
41 (31, 47) 36 (30, 47) |
33 (27, 40) 30 (27, 37) |
36 (29, 45) 36(29, 43) |
| GGT (U/L) | ||||
| Baseline Week 4 |
101 (61, 141) 49 (29, 73) |
164 (76, 246) 83 (35, 124) |
71 (42, 134) 35 (22, 65) |
93 (57, 163) 46(27, 88) *** |
| Bilirubin (mol/L) | ||||
| Baseline Week 4 |
9.5 (7.5, 13.0) 11.0 (8.5,12.0) |
9.5 (6.5, 3.5) 10.0 (6.0,15.0) |
9.5 (7.5, 12.0) 11.0 (8.0,15.0) |
9.5 (7, 13) 10 (8, 14) * |
| Albumin (g/L) | ||||
| Baseline Week 4 |
46.0 (2.5) 45.5 (2.7) |
47.4 (2.8) 47.3 (2.6) |
45.3 (2.1) 46.1 (2.2) |
46.2 (2.6) 46.3 (2.6) |
| Ferritin (μg/L) | ||||
| Baseline Week 4 |
228 (172) 295 (255) |
214 (190) 221 (166) |
254 (222) 241 (204) |
232 (194) 251(208) |
| Cholesterol (mmol/L) | ||||
| Total (Baseline) Total (Week 4) High-density (Baseline) High-density (Week 4) Low-density (Baseline) Low–density (Week 4) |
4.77 (0.98) 3.77 (1.05) 1.35 (0.43) 1.32 (0.40) 2.54 (0.74) 1.85 (0.72) |
5.16 (1.29) 3.78 (1.00) 1.41 (0.36) 1.37 (0.32) 2.88 (1.28) 1.94 (0.91) |
5.01 (0.86) 3.64 (0.76) 1.26 (0.27 1.18 (0.21) 2.96 (0.76) 1.96 (0.72) |
4.98 (1.06) 3.73 (0.93) *** 1.34 (0.36) 1.29 (0.32) * 2.79 (0.97) 1.92 (0.78) *** |
| Triglycerides (mmol/L) | ||||
| Baseline Week 4 |
2.01 (1.07) 0.98 (0.49) |
1.96 (0.80) 1.06 (0.46) |
1.74 (0.79) 1.07 (0.54) |
1.91 (0.89) 1.04 (0.49) *** |
| Type 2 diabetes | 7/20 | 7/20 | 7/20 | 21/60 |
| Fasting glucose (mmol/L) | ||||
| Baseline Week 4 |
6.32 (1.80) 5.70 (1.46) |
6.02 (1.70) 5.50 (1.39) |
6.07 (1.85) 5.19 (0.77) |
6.17 (1.77) 5.46 (1.23) *** |
| HbA1c (mmol/mol) | ||||
| Baseline Week 4 |
44.3 (11.5) 40.4 (8.3) |
48.1 (12.9) 42.5 (8.6) |
44.6 (11.5) 39.3 (7.4) |
45.6 (11.9) 40.7 (8.1) *** |
| CRP (mg/L) | ||||
| Baseline Week 4 |
2.0 (0.5, 4.0) 1.0 (0.5, 4.0) |
2.0 (1.0, 5.0) 0.8 (0.5, 3.0) |
2.5 (0.5, 6.0) 1.5 (0.5, 3.0) |
2.0 (0.5, 5.0) 1.0 (0.5, 3.0) ** |
| Fibroscan® CAP (dB/m) | ||||
| Baseline Week 4 |
307 (51) 267 (55) |
299 (58) 246 (51) |
296 (63) 258 (69) |
301 (57) 257 (58) *** |
Data are mean (SD), median (Q1, Q3) or number of patients. * p < 0.05, ** p < 0.01, *** p < 0.001 (paired t-test or Wilcoxon signed rank test).